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Abstract
Background/Aim. The real-life data were collected in order to assess the antiviral efficacy and safety of the direct-acting antiviral (DAA) regimen ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) + dasabuvir (DSV) +ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection, genotype 1. The study was multicentric and included seven infectious diseases and hepatology departments in Serbia.
Methods. A total of 21 patients were enrolled in the OBV/PTV/r +DSV + RBV early access program, 20 of which were previously treated with pegylated interferon+ribavirin, while one was treatment-naïve. All patients received the adequate doses of these antiviral drugs. RBV was not given to patients with HCV genotype 1b infection according to therapeutic protocol. For the majority of patient the treatment duration was 12 weeks. For patients with liver cirrhosis who were infected with HCV genotype 1a, the duration of treatment was 24 weeks. Viremia was assessed at four points in time: at baseline, 4 weeks after the beginning of treatment (rapid viral response, RVR), 12 or 24 weeks after the beginning of treatment (end of treatment response -ETR), and 12 weeks after the end of treatment (sustained viral response -SVR). SVR, as a confirmation of the absence of HCV was considered as endpoint of successful treatment.
Results. Complete RVR, ETR and SVR were achieved in 64.71%, 85.71%, and 95.24% patients, respectively. Only three patients had mild adverse effects which didn't required dose reduction. The aim of this prospective, multicentric, real-life clinical study was to evaluate the efficacy and safety of OBV/PTV/r+DSV therapeutic regimen in patients with chronic HCV infection in Serbia that were included in the early access program.
Methods
This real-life study was performed at seven infectology and hepatology departments of five Serbian universities in Belgrade, Novi Sad, Niš and Kragujevac.
Diagnostic and treatment approach to these patients was inspired by the Polish real-life (AMBER) study (14, 15) . A total of 21 male and female patients were included in this study. They had chronic HCV infection, caused by genotype 1, and majority of them were previously treated (non-responders or relapsers). Anatomical status of their livers was assessed by elastography (fibrosis scores F0-F4), while the hepatic functional status was assessed by values of bilirubin, albumin, international normalized ratio (INR), alanineaminotransferase (ALT), aspartate aminotransferase (AST) and presence of encephalopathy and ascites. Based on these parameters Child-Pugh score calculated in order to assess the existence of liver dysfunction. Some additional parameters were also estimated:
hemoglobin, red blood cell (RBC), white blood cell (WBC), platelet (PTL) counts and alpha-fetoprotein concentrations (AFP).
All patients in this study received the dose of OBV/PTV/r 12.5 mg/75 mg/5 mg, two tablets as a morning dose and DSV 250 mg dose of 500 mg/day divided in two doses. The dose of RBV, administered in 200 mg tablets, was 1000 mg/day for patients weighing <75 kg or 7 the dose of RBV in patients who developed severe adverse effects or laboratory abnormalities, such as anemia. RBV was given to all patients except to those with HCV genotype 1b. For the majority of patient the treatment duration was 12 weeks. Duration of treatment was extended to 24 weeks in high-risk patients, i.e. patients with liver cirrhosis who were infected with HCV genotype 1a.
Viremia was assessed at baseline, four weeks after beginning of treatment (RVR), 12 or 24 weeks after beginning of treatment (ETR), and 12 weeks after the end of treatment (SVR).
Number of replications of viral RNA was expressed in IU/ml. HCV levels were obtained by quantitative PCR essay. Viral RNA detection limit was ≥12 IU/ml.
Descriptive statistics such as calculation of mean values (ME) and their standard deviations (SD) were used.
Results
A total of 21 patients with HCV infection were included in this study. Twenty of them were previously treated with PEG-IFN and RBV, while one was treatment-naive. Among previously treated patients, 18 paients were null-responders and 2 patients were relapsers.
( Table 1 ).
All 21 patients were infected with genotype 1. In 11 of them sub-genotyping was not performed, 1 patient had a combined genotype 1a and 1b infection, 1 had a genotype 1a, while 8 were infected with genotype 1b. Out of 21 patients, 9 (42.85%) had fibrosis stages F3/F4, which are considered difficult to treat. Initial viremia varied over the large range of values (152x10 3 -527x10 6 IU/ml) with median 1.17x10 6 IU/ml). Liver function in these patients was well preserved with Child-Pugh score class A for 18 patients, with 3 patients without Child-Pugh score. All the biochemical and hematological parameters were within the normal range of values (Table 1) . Four-week RVR data were available in 17 patients. In 11(64%) HCV could not be found, 5
patients had low viral concentration (15-623 IU/ml) and only one patient had a significant viral load (99.000 IU/ml). ETR was estimated after 12 weeks of therapy in 18 patients and after 24 weeks of therapy in 3 high-risk patients. Complete ETR was achieved in 18 patients, in the rest of them the viral load was 12x10 3 , 192x10 3 and 1.24x10 6 . Full SVR estimated 12 weeks after the end of treatment was achieved in 20 patients, while only one had a significant viremia of 902x10 3 IU/ml (Figure 1 ). The used DAAs were well tolerated and no adverse events were recorded in 18 (85.71%) patients. The remaining three (14.29%) patients had adverse events. Two patients had hyperbilirubinemia and one had anemia, asthenia, fatigue, headache, insomnia and pruritus (Table 2 ). These side effects were mild and therefore the therapy did not have to be stopped, neither the reduction of RBV dose was needed. Life-threatening treatment emergent serious adverse event (SAE) wasn't recorded. antihypertensives, bronchodilators, thyreosuppressant and anti-anemic drugs, anti-ulcers drugs, levothyroxine and antidepressants (Table 3) . (11, (13) (14) (15) .
The onset of antiviral action was fast and it was similar to the one reported in a Polish clinical trial, where RVR was achieved in 69.23% (11) . In a systematic review of 19 clinical trials using the same therapeutic combination in patients with chronic HCV hepatitis, the average SVR of 97% was found (14) . SVR, as a confirmation of the absence of HCV was considered as endpoint of successful treatment and as a positive predictor of the patients' lower hepatic failure and mortality rates (16) .
The SVRs obtained in the present study and in the other ones with the OBV/PTV/r + DSV + RBV antiviral combination were significantly higher than in patients treated with pegylated interferon + RBV, 95-100% versus 70.5% (9) . The 2011 registration trials for the first generation protease inhibitors BOC and TVR, each combined with PEG-IFN+RBV, assured significantly lower SVRs of 59-66% (17) and 64-75% (18), respectively, while the subsequent real-life SVRs were even lower, 42-55% (10, 19) . Besides, the onset of the antiviral effect of the OBV/PTV/r + DSV + RBV was faster, with the vast majority of patients requiring only 12 weeks of treatment, while the duration of BOC or TVR regimens was 32-48 weeks (10, 19) .
All the treated patients in this study had infection with HCV genotype 1, which is in accordance with the epidemiological data obtained from Europe and the USA, where this genotype is dominant, in contrast with the data from Middle East, where genotype 4 prevails (12, 14, (20) (21) (22) . Local epidemiological and clinical studies also confirm the predominance of genotype 1 (6, 7, 9, 10).
Adverse events were mild and rare, occurring in 3 out of 21 patients (14.29%), all of them in those ones receiving RBV and not necessitating the decrease in the dose of RBV.
considerably higher incidence of adverse events (72.20%) was noted (14) . This difference could be explained by the fact that the population of patients in the present study was younger (average age 41.70 ± 11.59), without significant comorbidities, leaner (BMI 25.43 ± 3.82 kg/m 2 ) and with better preserved hepatic function than in the other trials (24) . The safety of the OBV/PTV/r + DSV + RBV antiviral combination in the present report was better than the one of the BOC or TVR-based triple regimens, where the incidence of adverse effects was very high, with anemia being the most important one (in 25% of patients), followed by neutropenia and thrombocytopenia (10) . It seems that the overall quality of life of patients treated with OBV/PTV/r + DSV + RBV is better than the one with BOC or TVR.
Conclusion.
In this real-life multicenter clinical study, DAA combination OBV/PTV/r + DSV + RBV assured excellent efficacy and tolerability in patients with genotype 1 chronic HCV infection.
